3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Unknown
1
Active not recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gynecologic
1
Conditions
Carcinoma, Non-Small-Cell Lung
26
Small Cell Lung Carcinoma
10
Sarcoma
8
Breast Neoplasms
8
Carcinoma, Hepatocellular
7
Lung Neoplasms
6
Stomach Neoplasms
5
Triple Negative Breast Neoplasms
4
Ovarian Neoplasms
4
Esophageal Squamous Cell Carcinoma
4
Carcinoma
4
Non-squamous Non-small Cell Lung Cancer
3
NSCLC
3
Glioma
3
Uterine Cervical Neoplasms
2
Urogenital Neoplasms
2
Thyroid Neoplasms
2
Pheochromocytoma
2
Paraganglioma
2
Neoplasms
2
Liver Neoplasms
2
Gynecological Cancer
2
Extensive Stage Small Cell Lung Cancer
2
Esophageal Neoplasms
2
Endometrial Neoplasms
2
Digestive System Neoplasms
2
Carcinoma, Ovarian Epithelial
2
Advanced Solid Tumor
2
Squamous Non-small Cell Lung Cancer
1
Squamous Cell Carcinoma of Head and Neck
1
Interventions
olaparib
1
niraparib
1
anlotinib
1
Sorafenib
1
Radiofrequency Ablation
1
Ocoxin
1
Chemoradiotherapy
1
Bevacizumab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Unknown
×
Neoplasms, Glandular and Epithelial
×
anlotinib
×
Clear all
NCT04566952
2020-10-30
ANLOLA
Jiangsu Cancer Institute & Hospital
Phase 2
Unknown
68 enrolled